Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18310258 | 1.00 | TMPRSS2 (0.42) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL20878440 | 1.00 | TMPRSS2 (0.42) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL20078639 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL17712511 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL17712266 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL24975093 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL17712509 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| Remdesivir SCHEMBL24494884 | 0.94 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| Remdesivir SCHEMBL22143154 | 0.94 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| Remdesivir SCHEMBL24611640 | 0.94 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4591935-A2 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4588928-A2 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4036099-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| EP-2595980-B1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012012776-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | TMPRSS2 3100/4885CYP3A4 2895/4885CYP2C9 4593/4885 |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | TMPRSS2 433/4885CYP3A4 1697/4885CYP2C9 3257/4885 |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | TMPRSS2 433/4885CYP3A4 1697/4885CYP2C9 3257/4885 |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | TMPRSS2 433/4885CYP3A4 1697/4885CYP2C9 3257/4885 |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | TMPRSS2 2447/4885CYP3A4 1932/4885CYP2C9 2637/4885 |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | TMPRSS2 2331/4885CYP3A4 2012/4885CYP2C9 2903/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | TMPRSS2 6/4885CYP3A4 296/4885CYP2C9 476/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | TMPRSS2 6/4885CYP3A4 296/4885CYP2C9 476/4885 |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | TMPRSS2 2331/4885CYP3A4 2012/4885CYP2C9 2903/4885 |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | PNP, SLC28A1, SLC29A1 | TMPRSS2 658/4885CYP3A4 1360/4885CYP2C9 262/4885 |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885CYP3A4 772/4885CYP2C9 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.